[
  {
    "ts": null,
    "headline": "Amgen’s gMG therapy cuts disease symptoms at one-year mark",
    "summary": "Results from the company’s Phase III Mint trial marked a median three-point improvement on a scale used to measure symptom impact.",
    "url": "https://finnhub.io/api/news?id=529e178c0165fe3707221cd3f527ab8d73217040dbe8c4350f7fc40e557d5b4b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741887066,
      "headline": "Amgen’s gMG therapy cuts disease symptoms at one-year mark",
      "id": 133185003,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Results from the company’s Phase III Mint trial marked a median three-point improvement on a scale used to measure symptom impact.",
      "url": "https://finnhub.io/api/news?id=529e178c0165fe3707221cd3f527ab8d73217040dbe8c4350f7fc40e557d5b4b"
    }
  },
  {
    "ts": null,
    "headline": "Amgen (NasdaqGS:AMGN) Announces Promising MINT Trial Data For UPLIZNA In Generalized Myasthenia Gravis",
    "summary": "Amgen (NasdaqGS:AMGN) has recently garnered attention due to promising Phase 3 MINT trial results for UPLIZNA in treating generalized myasthenia gravis, likely influencing its 14% price increase over the last quarter. These findings, emphasizing the drug's efficacy, coincide with Amgen's Q4 2024 earnings report, which showed a rise in revenue yet a decline in net income, reflecting a mixed financial performance. Despite the broader stock market experiencing declines, with the S&P 500 and...",
    "url": "https://finnhub.io/api/news?id=185b1b7e5403923af9a7b61a73d433af8b0629169469cfa68a655101c4bc05bc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741886479,
      "headline": "Amgen (NasdaqGS:AMGN) Announces Promising MINT Trial Data For UPLIZNA In Generalized Myasthenia Gravis",
      "id": 133185004,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (NasdaqGS:AMGN) has recently garnered attention due to promising Phase 3 MINT trial results for UPLIZNA in treating generalized myasthenia gravis, likely influencing its 14% price increase over the last quarter. These findings, emphasizing the drug's efficacy, coincide with Amgen's Q4 2024 earnings report, which showed a rise in revenue yet a decline in net income, reflecting a mixed financial performance. Despite the broader stock market experiencing declines, with the S&P 500 and...",
      "url": "https://finnhub.io/api/news?id=185b1b7e5403923af9a7b61a73d433af8b0629169469cfa68a655101c4bc05bc"
    }
  },
  {
    "ts": null,
    "headline": "Is Amgen Inc. (AMGN) the Best Pharma Stock to Buy According to Hedge Funds?",
    "summary": "We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against the other best pharma stocks to buy according to hedge funds. Why is China the Talk of the Town in the […]",
    "url": "https://finnhub.io/api/news?id=ad584a1229bea742457490e2e724913403c2596cf3542de599d0906fa8b77253",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741882159,
      "headline": "Is Amgen Inc. (AMGN) the Best Pharma Stock to Buy According to Hedge Funds?",
      "id": 133185005,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against the other best pharma stocks to buy according to hedge funds. Why is China the Talk of the Town in the […]",
      "url": "https://finnhub.io/api/news?id=ad584a1229bea742457490e2e724913403c2596cf3542de599d0906fa8b77253"
    }
  },
  {
    "ts": null,
    "headline": "Amgen's Uplizna Shows Improved Symptoms In Patients With Muscle Weakness Disorder Over One Year",
    "summary": "On Thursday, Amgen Inc (NASDAQ:AMGN) announced new data from the Phase 3 MINT trial of Uplizna (inebilizumab-cdon) for adult patients with generalized myasthenia gravis (gMG), a chronic autoimmune disease that causes muscle weakness. It affects the muscles used for breathing, swallowing, facial expressions, and movement. The results demonstrated the durable and sustained efficacy of Uplizna in patients with acetylcholine receptor autoantibody-positive (AChR+) gMG with two doses a year following",
    "url": "https://finnhub.io/api/news?id=df93a46db57475cf1e1d6e4bfbd1cbb495eb834505cdf3a71e6f34e328cfb387",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741880186,
      "headline": "Amgen's Uplizna Shows Improved Symptoms In Patients With Muscle Weakness Disorder Over One Year",
      "id": 133185006,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "On Thursday, Amgen Inc (NASDAQ:AMGN) announced new data from the Phase 3 MINT trial of Uplizna (inebilizumab-cdon) for adult patients with generalized myasthenia gravis (gMG), a chronic autoimmune disease that causes muscle weakness. It affects the muscles used for breathing, swallowing, facial expressions, and movement. The results demonstrated the durable and sustained efficacy of Uplizna in patients with acetylcholine receptor autoantibody-positive (AChR+) gMG with two doses a year following",
      "url": "https://finnhub.io/api/news?id=df93a46db57475cf1e1d6e4bfbd1cbb495eb834505cdf3a71e6f34e328cfb387"
    }
  },
  {
    "ts": null,
    "headline": "Exelixis (EXEL) Up 13.4% Since Last Earnings Report: Can It Continue?",
    "summary": "Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
    "url": "https://finnhub.io/api/news?id=ab3e6ced87929751718f055d8a160a40869f78e27b165e7d9e973304a0feef4f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741879829,
      "headline": "Exelixis (EXEL) Up 13.4% Since Last Earnings Report: Can It Continue?",
      "id": 133185007,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
      "url": "https://finnhub.io/api/news?id=ab3e6ced87929751718f055d8a160a40869f78e27b165e7d9e973304a0feef4f"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Says Phase 3 Data Support Uplizna's Efficacy in Generalized Myasthenia Gravis",
    "summary": "Amgen (AMGN) said Thursday said that a phase 3 trial of its Uplizna drug showed \"durable and sustain",
    "url": "https://finnhub.io/api/news?id=480b83dd43e9ceeedcd19f525459fd1a55406a1dd6164042b856b748adcb6069",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741874303,
      "headline": "Amgen Says Phase 3 Data Support Uplizna's Efficacy in Generalized Myasthenia Gravis",
      "id": 133185008,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (AMGN) said Thursday said that a phase 3 trial of its Uplizna drug showed \"durable and sustain",
      "url": "https://finnhub.io/api/news?id=480b83dd43e9ceeedcd19f525459fd1a55406a1dd6164042b856b748adcb6069"
    }
  },
  {
    "ts": null,
    "headline": "Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick",
    "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
    "url": "https://finnhub.io/api/news?id=d7bb7225c373d9ec0dbb2bde60b5846429726c47e990e017169b565bb62a5c3e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741873807,
      "headline": "Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick",
      "id": 133185009,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
      "url": "https://finnhub.io/api/news?id=d7bb7225c373d9ec0dbb2bde60b5846429726c47e990e017169b565bb62a5c3e"
    }
  },
  {
    "ts": null,
    "headline": "UPLIZNA® (INEBILIZUMAB-CDON) SIGNIFICANTLY IMPROVES GENERALIZED MYASTHENIA GRAVIS SYMPTOMS IN ACETYLCHOLINE RECEPTOR AUTOANTIBODY-POSITIVE PATIENTS OVER 52 WEEKS",
    "summary": "Amgen (NASDAQ:AMGN) today announced new data from the Phase 3, registrational MINT trial evaluating the efficacy and safety of UPLIZNA® (inebilizumab-cdon) in adults living with generalized myasthenia gravis (gMG). The results demonstrated durable and sustained efficacy of UPLIZNA in patients with acetylcholine receptor autoantibody-positive (AChR+) gMG with two doses a year, following an initial loading dose. Findings will be presented as a late-breaking oral presentation during the American Ac",
    "url": "https://finnhub.io/api/news?id=5756459ee02a0272ebc14702b0f097906e2b590c22b5fd744bb9b7bf6e57aff6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741870800,
      "headline": "UPLIZNA® (INEBILIZUMAB-CDON) SIGNIFICANTLY IMPROVES GENERALIZED MYASTHENIA GRAVIS SYMPTOMS IN ACETYLCHOLINE RECEPTOR AUTOANTIBODY-POSITIVE PATIENTS OVER 52 WEEKS",
      "id": 133185010,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (NASDAQ:AMGN) today announced new data from the Phase 3, registrational MINT trial evaluating the efficacy and safety of UPLIZNA® (inebilizumab-cdon) in adults living with generalized myasthenia gravis (gMG). The results demonstrated durable and sustained efficacy of UPLIZNA in patients with acetylcholine receptor autoantibody-positive (AChR+) gMG with two doses a year, following an initial loading dose. Findings will be presented as a late-breaking oral presentation during the American Ac",
      "url": "https://finnhub.io/api/news?id=5756459ee02a0272ebc14702b0f097906e2b590c22b5fd744bb9b7bf6e57aff6"
    }
  },
  {
    "ts": null,
    "headline": "Uplizna Significantly Improves Generalized Myasthenia Gravis Symptoms In Acetylcholine Receptor Autoantibody-Positive Patients Over 52 Weeks",
    "summary": "Amgen Inc: * UPLIZNA® SIGNIFICANTLY IMPROVESGENERALIZEDMYASTHENIA GRAVIS SYMPTOMS IN ACETYLCHOLINE RECEPTORAUTOANTIBODY-POSITIVE PATIENTS OVER 52 WEEKS * AMGEN INC: NO...",
    "url": "https://finnhub.io/api/news?id=29f431b2a22132e350e480f60777ebbe838c5630f9976cd7aac4c0e75b21a0c9",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741863142,
      "headline": "Uplizna Significantly Improves Generalized Myasthenia Gravis Symptoms In Acetylcholine Receptor Autoantibody-Positive Patients Over 52 Weeks",
      "id": 133162804,
      "image": "",
      "related": "AMGN",
      "source": "Finnhub",
      "summary": "Amgen Inc: * UPLIZNA® SIGNIFICANTLY IMPROVESGENERALIZEDMYASTHENIA GRAVIS SYMPTOMS IN ACETYLCHOLINE RECEPTORAUTOANTIBODY-POSITIVE PATIENTS OVER 52 WEEKS * AMGEN INC: NO...",
      "url": "https://finnhub.io/api/news?id=29f431b2a22132e350e480f60777ebbe838c5630f9976cd7aac4c0e75b21a0c9"
    }
  }
]